Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 31;22:66. doi: 10.1186/s12943-023-01743-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — CDR1as promoted EMT in cervical cancer cells via binding with IGF2BP1. A qPCR was performed after pull-down using CDR1as probe; B Silver staining was performed after pull-down using CDR1as probe, a distinct band was discovered at 70 kD; C Western blot assay was performed after pull-down using CDR1as probe; D RIP assay using anti-IGF2BP1 shows an obvious enrichment of CDR1as; E qPCR was performed after IGF2BP1 was silenced; F, G, H Primers were designed for Slug’s M6A modification site, RIP assay using anti-m6A and anti- IGF2BP1 showed evident enrichment of Slug; I inhibition of IGF2BP1 reduced CDR1as-promoted metastatic and invasive potential